330 related articles for article (PubMed ID: 20500532)
1. The suppression of immune activation during enfuvirtide-based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin-12 and IP-10 during 48 weeks of longitudinal follow-up.
Carsenti-Dellamonica H; Saïdi H; Ticchioni M; Guillouet de Salvador F; Dufayard Cottalorda J; Garraffo R; Dellamonica P; Durant J; Gougeon ML
HIV Med; 2011 Feb; 12(2):65-77. PubMed ID: 20500532
[TBL] [Abstract][Full Text] [Related]
2. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
[TBL] [Abstract][Full Text] [Related]
3. The effect of a year of highly active antiretroviral therapy on immune reconstruction and cytokines in HIV/AIDS patients.
Yao Y; Luo Y; He Y; Zheng Y; Zhang Q; Zhou H; Zeng S; Chen Z; He B; He M
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):691-7. PubMed ID: 23151174
[TBL] [Abstract][Full Text] [Related]
4. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
Poveda E; Rodés B; Labernardière JL; Benito JM; Toro C; González-Lahoz J; Faudon JL; Clavel F; Schapiro J; Soriano V
J Med Virol; 2004 Sep; 74(1):21-8. PubMed ID: 15258964
[TBL] [Abstract][Full Text] [Related]
5. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
Aquaro S; D'Arrigo R; Svicher V; Perri GD; Caputo SL; Visco-Comandini U; Santoro M; Bertoli A; Mazzotta F; Bonora S; Tozzi V; Bellagamba R; Zaccarelli M; Narciso P; Antinori A; Perno CF
J Antimicrob Chemother; 2006 Oct; 58(4):714-22. PubMed ID: 16891628
[TBL] [Abstract][Full Text] [Related]
6. Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5.
Rucker RP; Day NK; Good RA; Kamchaisatian W; Emmanuel P; Sleasman JW; Mayeski C; Dinglasan E; Haraguchi S; Tangsinmankong N
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):272-6. PubMed ID: 15478388
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
8. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
9. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.
Raffi F; Katlama C; Saag M; Wilkinson M; Chung J; Smiley L; Salgo M
Clin Infect Dis; 2006 Mar; 42(6):870-7. PubMed ID: 16477567
[TBL] [Abstract][Full Text] [Related]
10. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
[TBL] [Abstract][Full Text] [Related]
11. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
[TBL] [Abstract][Full Text] [Related]
12. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.
Melby TE; Despirito M; Demasi RA; Heilek G; Thommes JA; Greenberg ML; Graham N
AIDS; 2007 Nov; 21(18):2537-9. PubMed ID: 18025893
[TBL] [Abstract][Full Text] [Related]
13. Immunological and virological study of enfuvirtide-treated HIV-positive patients.
Barretina J; Blanco J; Bonjoch A; Llano A; Clotet B; Esté JA
AIDS; 2004 Aug; 18(12):1673-82. PubMed ID: 15280778
[TBL] [Abstract][Full Text] [Related]
14. Virological fitness of HIV in patients with resistance to enfuvirtide.
Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
[TBL] [Abstract][Full Text] [Related]
15. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N
J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700
[TBL] [Abstract][Full Text] [Related]
16. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.
Losana G; Bovolenta C; Rigamonti L; Borghi I; Altare F; Jouanguy E; Forni G; Casanova JL; Sherry B; Mengozzi M; Trinchieri G; Poli G; Gerosa F; Novelli F
J Leukoc Biol; 2002 Oct; 72(4):735-42. PubMed ID: 12377943
[TBL] [Abstract][Full Text] [Related]
17. Persistent HIV-1 replication does not explain low levels of T-cell interferon-gamma mRNA and elevated serum NO(2) (-)/NO(3) (-) in patients with stable CD4 T-cell responses to HAART.
Lee S; Almeida CA; French MA; Price P
Clin Exp Immunol; 2004 Oct; 138(1):110-5. PubMed ID: 15373912
[TBL] [Abstract][Full Text] [Related]
18. Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses.
Blazevic V; Jankelevich S; Steinberg SM; Jacobsen F; Yarchoan R; Shearer GM
Clin Diagn Lab Immunol; 2001 Sep; 8(5):943-8. PubMed ID: 11527808
[TBL] [Abstract][Full Text] [Related]
19. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
[TBL] [Abstract][Full Text] [Related]
20. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
Kourtis AP; Ibegbu CC; Theiler R; Xu YX; Bansil P; Jamieson DJ; Lindsay M; Butera S; Duerr A
J Infect Dis; 2007 Apr; 195(7):965-72. PubMed ID: 17330786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
